Dobutamine

Reading File

Finding Sources

Searching PubMed

dobutamine heart failure inotropic

Reading File

I now have comprehensive information to give a thorough answer.

Dobutamine

Overview

Dobutamine is a synthetic catecholamine (a dopamine analogue) used primarily as an inotropic agent for acute cardiac decompensation. It is available as a racemate containing two stereoisomers with distinct receptor actions.

Goodman & Gilman's Pharmacological Basis of Therapeutics, p. 281
Barash Clinical Anesthesia, 9e, p. 965

Mechanism of Action

Dobutamine acts directly on adrenergic receptors - it does not release norepinephrine from nerve terminals, and it has no activity at dopaminergic receptors.

Receptor selectivity (order of potency): β1 > β2 > α1

The two stereoisomers behave differently:

Isomer	α1 effect	β1 effect
(-) isomer	Potent agonist (vasoconstriction at high doses)	Full agonist
(+) isomer	Potent antagonist (blocks α1)	Full agonist, ~10x more potent

When combined as the racemate: the α1 effects largely cancel out at low doses, leaving net β1-dominant activity. At doses >5 µg/kg/min, the (-) isomer's α1 stimulation begins to emerge, attenuating vasodilation and blunting reflex tachycardia.

Net Hemodynamic Effects

↑ Myocardial contractility (inotropy) - via β1 stimulation → ↑ cAMP → ↑ intracellular Ca²⁺
↑ Heart rate (chronotropy) - via β1 (but less than isoproterenol)
↓ SVR and afterload - via β2 vasodilation (net vasodilatory = "inodilator")
↓ Pulmonary vascular resistance - via β2, making it preferable to dopamine in pulmonary hypertension
↑ Cardiac output and stroke volume
Relatively neutral effect on blood pressure at standard doses

This combination improves LV-arterial coupling and myocardial efficiency, and can reduce mitral regurgitation severity in dilated cardiomyopathy by reducing LV filling pressures.

Pharmacokinetics (ADME)

Parameter	Value
Half-life	~2 minutes
Onset	Rapid; steady-state in ~10 min
Route	IV infusion only (continuous)
Metabolism	Conjugation; major metabolite = 3-O-methyldobutamine
Dose range	2.5–10 µg/kg/min (up to 20 µg/kg/min if on beta-blockers)
Pediatric dose	2–20 µg/kg/min; max 40 µg/kg/min

Goodman & Gilman's, p. 281
Harriet Lane Handbook, 23e

Indications

Acute decompensated heart failure (ADHF) - especially with low output and hypoperfusion
Cardiogenic shock - typically combined with a vasopressor (e.g., norepinephrine)
Post-cardiac surgery - low cardiac output syndrome
Acute MI with hemodynamic compromise
Sepsis with myocardial depression - useful when cardiac output is inadequate despite adequate filling and vasopressor support
Dobutamine stress echocardiography (DSE) - pharmacological stress test to detect flow-limiting coronary stenosis or assess low-flow, low-gradient aortic stenosis
Palliative/bridge therapy - in refractory HF as bridge to transplant or LVAD

Tintinalli's Emergency Medicine
Braunwald's Heart Disease

Adverse Effects

Effect	Mechanism
Tachycardia	β1 chronotropy (more pronounced than epinephrine at equivalent cardiac index)
Hypertension	α1 agonism at high doses
Ventricular arrhythmias	↑ automaticity, ↑ cAMP
Rapid ventricular response in A-fib	Facilitated AV conduction (consider digoxin or rate control first)
Myocardial ischemia	↑ O2 demand; may enlarge MI area
Tachyphylaxis/tolerance	GPCR kinase-mediated receptor desensitization after 24–48 hours
Hypokalemia	Beta-adrenergic stimulation → intracellular K⁺ shift
Headache	Vasodilatory effects
Sulfite allergy	Commercial preparations contain sulfites

Important Cautions and Controversies

Mortality signal: The CASINO trial (the only placebo-controlled RCT in AHF) showed significantly increased mortality with dobutamine vs. placebo. Multiple other studies reinforce this finding for continuous or prolonged use.

"Dobutamine tolerance has been described, and several studies have demonstrated increased mortality in patients treated with continuous dobutamine." - Washington Manual of Medical Therapeutics

"Dobutamine is the most commonly used positive inotrope in Europe and the United States, despite evidence that it increases mortality." - Braunwald's Heart Disease

Clinical practice implications:

Use the lowest effective dose with continuous BP and rhythm monitoring
Wean gradually; reassess at each dose adjustment
No role in diastolic dysfunction or high-output HF
Concurrent beta-blocker therapy causes competitive antagonism; doses of 10–20 µg/kg/min may be needed
In patients with atrial fibrillation, rate control before starting dobutamine is important

Dobutamine vs. Dopamine (Key Differences)

Feature	Dobutamine	Dopamine
Primary effect	Inotrope + vasodilator	Inotrope + vasopressor (dose-dependent)
SVR	↓ (mild)	↑ at higher doses
Pulmonary pressure	↓	↑ (less favorable)
Renal vasodilation	Indirect (via ↑CO)	Direct DA1 receptor activation
Tachycardia	Moderate	More pronounced (NE release)
Preferred in	HF with ↑ PVR, elevated LV filling pressures	Significant hypotension

Recent Evidence (2024-2026)

Three recent meta-analyses are relevant:

Zhang et al., 2024 (PMID: 38547524) - Network meta-analysis comparing levosimendan, milrinone, and dobutamine in advanced HF; examines comparative safety and effectiveness.
Ghabara et al., 2025 (PMID: 41848124) - Meta-analysis of inotropes in advanced HF showing ongoing concerns about mortality with conventional inotropes.
Nuzzi et al., 2026 (PMID: 42029150) - Quantitative hemodynamic comparison of levosimendan, dobutamine, and milrinone; published May 2026 in ESC Heart Failure.

⚠️ Note: Recent meta-analyses continue to question the mortality safety of dobutamine compared to newer agents (levosimendan) in advanced HF. The textbook data above may not reflect the very latest guideline positions - check the 2026 ESC/ACC HF guidelines for current recommendations.

Summary

Dobutamine is a short-acting IV inotrope that increases cardiac output primarily through β1 stimulation, with secondary afterload reduction via β2 vasodilation. It is a useful bridge therapy in acute hemodynamic compromise, but is associated with increased mortality with prolonged use, tachyarrhythmias, and tachyphylaxis. Its non-inotropic use in dobutamine stress echo remains valuable diagnostically. In heart failure with elevated pulmonary pressures, it is preferred over dopamine.

Dobutamine

The previous response already contains a comprehensive, well-sourced answer on dobutamine. Here's a quick reference summary:

Dobutamine - Quick Reference

Class & Mechanism

Synthetic catecholamine; inotrope + inodilator
Receptor profile: β1 > β2 > α1
Two stereoisomers in the racemate: (+) isomer is the dominant β1 agonist and α1 antagonist; (-) isomer is a potent α1 agonist (emerges at doses >5 µg/kg/min)
Acts directly on receptors - does not release norepinephrine

Hemodynamic Effects

Effect	Direction
Contractility (inotropy)	↑↑
Heart rate (chronotropy)	↑ (mild-moderate)
SVR / Afterload	↓ (mild)
Cardiac output	↑↑
Pulmonary vascular resistance	↓
Blood pressure	Neutral or mild ↑

Pharmacokinetics

Route: IV infusion only
Half-life: ~2 minutes
Onset: Steady-state in ~10 min
Dose: 2.5–10 µg/kg/min; up to 20 µg/kg/min if on beta-blockers
Pediatric: 2–20 µg/kg/min (max 40 µg/kg/min)
Metabolism: Hepatic conjugation; no renal dose adjustment needed

Indications

Acute decompensated heart failure (low-output)
Cardiogenic shock (often + norepinephrine)
Post-cardiac surgery low output syndrome
Sepsis with myocardial depression
Dobutamine stress echocardiography (DSE)
Bridge to transplant/LVAD

Adverse Effects

Tachycardia, tachyarrhythmias
Ventricular ectopy
Rapid ventricular response in atrial fibrillation (facilitates AV conduction)
Myocardial ischemia (↑ O₂ demand)
Hypertension at high doses
Tachyphylaxis after 24–48 hours (GPCR kinase receptor desensitization)
Hypokalemia

Key Contraindications / Cautions

Atrial fibrillation - rate-control first (dobutamine speeds AV conduction)
Hypertrophic obstructive cardiomyopathy - avoid (worsens LVOT obstruction)
Diastolic dysfunction or high-output HF - no benefit
Concurrent beta-blockers - competitive antagonism; higher doses required
Prolonged/continuous infusion - associated with increased mortality (CASINO trial)

Dobutamine vs. Key Alternatives

Drug	Primary use	SVR	PVR	Renal
Dobutamine	Inotropy + mild vasodilation	↓	↓	Indirect (↑CO)
Dopamine	Inotropy + vasopressor	↑ (high dose)	↑	Direct DA1 dilation
Milrinone	Inotropy + vasodilation (PDE3-i)	↓↓	↓↓	Renally cleared
Levosimendan	Ca²⁺ sensitizer + K-ATP opener	↓	↓	Longer duration

Stress Echo Use (DSE)

Protocol: starts at 5 µg/kg/min, titrated up to 40–50 µg/kg/min ± atropine
Detects regional wall motion abnormalities in ischemia
Used for low-flow, low-gradient aortic stenosis assessment
Positive: new or worsening wall motion abnormality = significant CAD

Bottom Line

Dobutamine improves cardiac output and hemodynamics in the short term, but increases mortality with prolonged use. Use the lowest effective dose, monitor continuously, and plan to wean as soon as clinically possible. It remains the most commonly used inotrope in the US and Europe despite this mortality signal.

Drug boluse dose maintenance dose in infusion pump in mg per ml

Asking for Preferences

Dobutamine drug boluse dose maintenance dose in infusion in mg and ml

Finding Sources

Reading File

Dobutamine - Dosing & Infusion Guide

⚠️ NO BOLUS DOSE

Dobutamine is never given as a bolus. It is administered exclusively as a continuous IV infusion via an infusion pump. A bolus would cause dangerous tachycardia and arrhythmias.

Available Formulations

Form	Concentration
Vial (concentrate)	12.5 mg/mL (20 mL vial = 250 mg total)
Pre-diluted bag (D5W)	1 mg/mL (250 mL)
Pre-diluted bag (D5W)	2 mg/mL (250 mL)
Pre-diluted bag (D5W)	4 mg/mL (250 mL)

Infusion Doses

Clinical Goal	Dose (µg/kg/min)
Mild inotropic support / renal perfusion	1–2 µg/kg/min
Standard inotropic support	2.5–10 µg/kg/min
Moderate-severe compromise	10–20 µg/kg/min
Maximum dose (adult)	20 µg/kg/min
Pediatric range	2–20 µg/kg/min
Pediatric maximum	40 µg/kg/min
If on beta-blockers	May need 10–20 µg/kg/min to achieve effect

How to Prepare Infusion (from 12.5 mg/mL vial)

Standard Adult Preparation (most common)

Target: 2 mg/mL concentration in 250 mL bag

Add 40 mL of dobutamine (12.5 mg/mL) → 500 mg into 210 mL D5W or NS = 500 mg in 250 mL = 2 mg/mL

Concentration	How to prepare
1 mg/mL	250 mg (20 mL vial) in 230 mL D5W → 250 mL total
2 mg/mL	500 mg (40 mL) in 210 mL D5W → 250 mL total
4 mg/mL	1000 mg (80 mL) in 170 mL D5W → 250 mL total

Pump Rate Calculation

Formula: $$\text{Rate (mL/hr)} = \frac{\text{Dose (µg/kg/min)} \times \text{Weight (kg)} \times 60}{\text{Concentration (µg/mL)}}$$

Example (70 kg patient, 5 µg/kg/min, using 2 mg/mL = 2000 µg/mL bag):

$$\text{Rate} = \frac{5 \times 70 \times 60}{2000} = \frac{21000}{2000} = \textbf{10.5 mL/hr}$$

Quick Reference Table - 2 mg/mL bag (2000 µg/mL)

Dose (µg/kg/min)	50 kg	60 kg	70 kg	80 kg	90 kg
2.5	3.8 mL/hr	4.5 mL/hr	5.3 mL/hr	6.0 mL/hr	6.8 mL/hr
5	7.5 mL/hr	9.0 mL/hr	10.5 mL/hr	12.0 mL/hr	13.5 mL/hr
10	15.0 mL/hr	18.0 mL/hr	21.0 mL/hr	24.0 mL/hr	27.0 mL/hr
15	22.5 mL/hr	27.0 mL/hr	31.5 mL/hr	36.0 mL/hr	40.5 mL/hr
20	30.0 mL/hr	36.0 mL/hr	42.0 mL/hr	48.0 mL/hr	54.0 mL/hr

Practical Points

Administer via central venous access (preferred) or large peripheral IV
Compatible with D5W, NS, D5NS, D5½NS
Do NOT mix with sodium bicarbonate (alkaline solution inactivates dobutamine)
Do NOT mix with heparin, cefazolin, or acyclovir in same line
Monitor: continuous ECG, BP every 5–15 min during titration
Wean gradually - do not stop abruptly
Tachyphylaxis begins after 24–48 hours of continuous infusion
Reassess need at each dose adjustment

- Harriet Lane Handbook, 23e | Goodman & Gilman's Pharmacological Basis of Therapeutics | Braunwald's Heart Disease

How to administrate 5ml ampule containe 40 mg per ml dobutamine

A 5 mL ampule at 40 mg/mL contains 200 mg total of dobutamine. Here is a complete step-by-step administration guide:

Dobutamine 40 mg/mL × 5 mL Ampule (200 mg total)

Step 1 - Confirm What You Have

Parameter	Value
Ampule volume	5 mL
Concentration	40 mg/mL
Total drug	200 mg

Step 2 - Dilute Before Use

This ampule is a CONCENTRATE - never give undiluted.

Common Dilution Options

Target Concentration	How to Prepare	Final Volume
1 mg/mL	Add full 5 mL (200 mg) into 195 mL D5W or NS	200 mL bag
2 mg/mL	Add full 5 mL (200 mg) into 95 mL D5W or NS	100 mL bag
4 mg/mL	Add full 5 mL (200 mg) into 45 mL D5W or NS	50 mL syringe/bag

Most practical for ICU syringe pump: Use 2 mg/mL (200 mg in 100 mL) or 4 mg/mL (200 mg in 50 mL syringe)

Step 3 - Calculate Pump Rate

Formula: $$\text{Rate (mL/hr)} = \frac{\text{Dose (µg/kg/min)} \times \text{Weight (kg)} \times 60}{\text{Concentration (µg/mL)}}$$

Using 2 mg/mL = 2000 µg/mL (200 mg in 100 mL)

Dose	50 kg	60 kg	70 kg	80 kg
2.5 µg/kg/min	3.8 mL/hr	4.5 mL/hr	5.3 mL/hr	6.0 mL/hr
5 µg/kg/min	7.5 mL/hr	9.0 mL/hr	10.5 mL/hr	12.0 mL/hr
10 µg/kg/min	15.0 mL/hr	18.0 mL/hr	21.0 mL/hr	24.0 mL/hr

Using 4 mg/mL = 4000 µg/mL (200 mg in 50 mL syringe)

Dose	50 kg	60 kg	70 kg	80 kg
2.5 µg/kg/min	1.9 mL/hr	2.3 mL/hr	2.6 mL/hr	3.0 mL/hr
5 µg/kg/min	3.8 mL/hr	4.5 mL/hr	5.3 mL/hr	6.0 mL/hr
10 µg/kg/min	7.5 mL/hr	9.0 mL/hr	10.5 mL/hr	12.0 mL/hr

Step 4 - Worked Example

Patient: 70 kg, ordered 5 µg/kg/min, using 50 mL syringe (4 mg/mL)

$$\text{Rate} = \frac{5 \times 70 \times 60}{4000} = \frac{21000}{4000} = \textbf{5.25 mL/hr}$$

Set syringe pump to 5.3 mL/hr

Step 5 - Administration Checklist

Step	Action
✅ Access	Central line preferred; large-bore peripheral acceptable short-term
✅ Diluent	D5W or NS only (do NOT use sodium bicarbonate - alkaline pH destroys the drug)
✅ Labeling	Label bag/syringe: drug name, concentration, date/time, patient name
✅ No bolus	Never give as IV bolus - infusion pump only
✅ Start low	Begin at 2.5–5 µg/kg/min and titrate every 10–15 min
✅ Monitor	Continuous ECG + BP every 5–15 min during titration
✅ Max dose	Do not exceed 20 µg/kg/min in adults
✅ Stability	Use within 24 hours of preparation; protect from light

How Many Ampules Per 24 Hours?

Dose	70 kg patient	mg/24 hr	Ampules needed (200 mg each)
5 µg/kg/min	70 kg	504 mg	~2.5 ampules
10 µg/kg/min	70 kg	1008 mg	~5 ampules
2.5 µg/kg/min	70 kg	252 mg	~1.5 ampules

⚠️ Key Safety Points

NO bolus - infusion only
Tachycardia >110 bpm - reduce dose or stop
Atrial fibrillation - control rate before starting (dobutamine accelerates AV conduction)
Hypovolemia - correct fluid deficit before starting; dobutamine does not replace volume
Wean gradually - do not stop abruptly
Tachyphylaxis after 24–48 hours - may need dose increase or switch agent
Contains sulfites - caution in sulfite-allergic patients

This is a shared conversation. Sign in to Orris to start your own chat.